Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women
- PMID: 22678035
- PMCID: PMC4043143
- DOI: 10.1097/AOG.0b013e318259565a
Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women
Abstract
Objective: To estimate the contraceptive failure rates of the etonogestrel subdermal contraceptive implant in overweight and obese women and compare failure rates with women of normal weight and women using intrauterine devices (IUDs).
Methods: The Contraceptive CHOICE Project is a large prospective cohort study designed to promote the use of long-acting reversible contraceptive methods to reduce unintended pregnancies in the St Louis region. Participants are provided reversible contraception of their choice at no cost. We collected baseline height and weight of each participant. During each survey, participants were asked about missed menses and possible pregnancies. Any participant who suspected a pregnancy was asked to come in for urine pregnancy testing. Analysis includes the first 8,445 participants enrolled in CHOICE of which 1,168 chose the implant and 4,200 chose the IUD. Student's t test, χ test, and Kaplan-Meier survival curves were used to perform statistical analyses to estimate failure rates in overweight and obese women using the implant and IUDs.
Results: Of the women choosing the implant, 28% were overweight and 35% were obese. Of the women who chose an IUD, 27% were overweight and 35% were obese. The 3-year cumulative failure rates for implant and IUD users were less than one per 100 women-years and did not vary by body mass index.
Conclusion: We found no decrease in the effectiveness of the implant in overweight or obese women. The implant may be offered as a first-line contraceptive method to any woman seeking a reversible and reliable birth control method.
Conflict of interest statement
Similar articles
-
Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.Am J Obstet Gynecol. 2017 Jun;216(6):586.e1-586.e6. doi: 10.1016/j.ajog.2017.01.036. Epub 2017 Jan 29. Am J Obstet Gynecol. 2017. PMID: 28147241 Free PMC article.
-
Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.Contraception. 2015 Dec;92(6):553-9. doi: 10.1016/j.contraception.2015.06.013. Epub 2015 Jun 17. Contraception. 2015. PMID: 26093190
-
Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.Am J Obstet Gynecol. 2017 Feb;216(2):101-109. doi: 10.1016/j.ajog.2016.08.033. Epub 2016 Sep 20. Am J Obstet Gynecol. 2017. PMID: 27662799 Free PMC article. Clinical Trial.
-
Long-acting reversible contraception: a review in special populations.Pharmacotherapy. 2014 Jan;34(1):46-59. doi: 10.1002/phar.1358. Epub 2013 Oct 15. Pharmacotherapy. 2014. PMID: 24130075 Review.
-
Subdermal contraceptive implants.J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):223-6. doi: 10.1016/0960-0760(95)00051-z. J Steroid Biochem Mol Biol. 1995. PMID: 7626459 Review.
Cited by
-
Obesity and contraception.Clin Obstet Gynecol. 2014 Sep;57(3):501-7. doi: 10.1097/GRF.0000000000000047. Clin Obstet Gynecol. 2014. PMID: 25029338 Free PMC article. Review.
-
Hormonal contraceptives for contraception in overweight or obese women.Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4. Cochrane Database Syst Rev. 2016. PMID: 27537097 Free PMC article.
-
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.Contraception. 2019 Oct;100(4):288-295. doi: 10.1016/j.contraception.2019.06.011. Epub 2019 Jun 24. Contraception. 2019. PMID: 31247193 Free PMC article.
-
Long-Acting Reversible Contraception.N Engl J Med. 2017 Feb 2;376(5):461-468. doi: 10.1056/NEJMcp1608736. N Engl J Med. 2017. PMID: 28146650 Free PMC article. Review.
-
What do I need to know about the etonogestrel-relesasing contraceptive implant (Nexplanon)?Paediatr Child Health. 2021 May 27;26(7):394-395. doi: 10.1093/pch/pxab014. eCollection 2021 Nov. Paediatr Child Health. 2021. PMID: 34777656 Free PMC article. No abstract available.
References
-
- McDonald-Mosley R, Burke AE. Contraceptive implants. Semin Reprod Med. 2010;28:110–117. - PubMed
-
- Steiner MJ. Contraceptive effectiveness: what should the counseling message be? JAMA. 1999;282:1405–7. - PubMed
-
- Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91(5):1646–1653. - PubMed
-
- Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38:90–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical